Persistent HPV infection and cervical cancer risk: Is the scientific rationale for changing the screening paradigm enough?

Journal of the National Cancer Institute

Volumn 102, Issue 19, 2010, Pages 1451-1453

  Franco, Eduardo L ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

CANCER CYTODIAGNOSIS; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; EDITORIAL; FALSE NEGATIVE RESULT; GENOTYPE; HEALTH CARE QUALITY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 53; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 68; NORTH AMERICA; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PUBLIC HEALTH; RISK ASSESSMENT; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; WESTERN EUROPE; CERVICAL INTRAEPITHELIAL NEOPLASIA; COMPLICATION; DENMARK; FEMALE; ISOLATION AND PURIFICATION; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; STANDARDS; TIME; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINA SMEAR; VIROLOGY;

CERVICAL INTRAEPITHELIAL NEOPLASIA; DENMARK; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; TIME FACTORS; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 77957850272     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq357     Document Type: Editorial

References (14)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-19.
2. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119(5):1095-1101.
3. Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W, Paraskevaidis E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol. 2007;104(1):232-246.
4. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papilloma-virus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357(16):1579-1588.
5. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337:a1754doi: 10.1136/bmj. a1754.
6. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370(9601):1764-1772.
7. Naucler P, Ryd W, Törnberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007; 357(16):1589-1597.
8. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Effcacy of human papillo-mavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial [published online ahead of print January 18, 2010]. Lancet Oncol. 2010;11(3): 249-257.
9. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009;360(14):1385-1394.
10. Kjær SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papil-lomavirus infection: role of persistence. J Natl Cancer Inst. 2010;102(19): 1478-1488.
11. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specifc HPV testing in clinical practice. J Natl Cancer Inst. 2005;97(14):1072-1079.
12. Schiffman M, Rodriguez AC, Chen Z, et al. A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Cancer Res. 2010;70(8):3159-3169.
13. Katki HA, Wacholder S, Solomon D, Castle PE, Schiffman M. Risk estimation for the next generation of prevention programmes for cervical cancer. Lancet Oncol. 2009;10(11):1022-1023.
14. Anttila A, Kotaniemi-Talonen L, Leinonen M, et al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ. 2010;340:c1804doi:10.1136/bmj.c1804.